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ABSTRACT
Monocyte chemoattractant protein-1 (MCP-1) is produced by different cells in response to inflammatory stim-
ulation. In the present study, a series of human MCP-1 promoter reporter genes were constructed to illus-
trate elements involved in antioxidant dimethyl sulfoxide (DMSO) inhibition of MCP-1 gene expression. MCP-
1 secretion and mRNA expression and transcription activity stimulated by TNF- or IL-1 were significantly
inhibited by 1% DMSO in alveolar type II epithelial cells (A549). Deletion of 7537 to 2741 caused a 77%
decrease in reporter activity, but DMSO inhibition was still present. Deletion of 7537 to 2616 containing
the A1 NF-B binding site resulted in a complete loss of MCP-1 stimulation. Deletion of 2585 to 74 de-
creased reporter activity by 50%, and DMSO inhibited this induction. Deletion of 2614 to 74 contain-
ing the A2 NF-B binding site completely abolished responses to stimulation. Mutations of either of the NF-
B binding sites decreased promoter activity, which could still be inhibited by DMSO, whereas deletion of
both NF-B binding sites abolished induced transcriptional activity. Mutation or deletion of the NF-B bind-
ing sites significantly decreased or abolished reporter activity in response to reactive oxygen intermediates
(ROI), generated by xanthine plus xanthine oxidase. In conclusion, DMSO inhibits MCP-1 gene expression
through both NF-B binding sites located far upstream of the 5-flanking region of the MCP-1 promoter.
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INTRODUCTION
BLOOD MONOCYTES infiltrate into the sites of inflammationand play major roles in host defense through their ability
to present antigens and to produce various mediators. Although
the mechanisms of monocyte infiltration have not been fully
understood, locally produced monocyte chemoattractants ap-
pear to be responsible for the recruitment of blood monocytes
into the sites of inflammatory reactions.
Monocyte chemoattractant protein-1 (MCP-1) is a member
of the CC subfamily of the chemokines and attracts blood mono-
cytes both in vitro and in vivo (1). MCP-1 was initially char-
acterized as a monocyte-specific chemoattractant in vitro (34),
but was subsequently shown also to attract memory T lym-
phocytes, natural killer cells, and neutrophils. A wide variety
of cells, including monocytes, fibroblasts, vascular endothelial
cells, and smooth muscle cells, produce MCP-1 in vitro in re-
sponse to stimuli such as IL-1, TNF-, platelet-derived growth
factor, IFN-, and lipopolysaccharide (LPS). MCP-1 has been
implicated in the pathology of various diseases characterized
by a mononuclear cell infiltrate. Rosseau et al. (26) reported
that upregulation of MCP-1 synthesis and its secretion into the
alveolar space is the central event in the early expansion of the
alveolar mononuclear phagocyte population observed in pa-
tients with ARDS, mainly because of a rapid influx of mono-
cytes from the vascular compartment. These events were found
to be significantly correlated with the severity of respiratory
failure.
Reactive oxygen intermediates (ROIs) are widely involved
in different phases of the inflammatory reaction. Recent stud-
ies have linked oxidants to stimulation of cytokine and chemo-
kine production through modulation of certain transcriptional
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activating proteins (17, 19, 27). Other studies (30, 32) showed
that ROIs, such as those generated by hyperoxia, have an ef-
fect on MCP-1 and IL-8 production (6). ROIs have also been
shown to be necessary intermediates in calcium oxalate crys-
tal–induced MCP-1 production (33). MCP-1 production is en-
hanced by a variety of oxidants through increased transcription
(32). Previous work demonstrated that treatment with the anti-
oxidant DMSO attenuates LPS-induced secretion of the CXC
chemokine IL-8 (8, 30), supporting the hypothesis that oxidants
may act as second messengers in the initiation of chemokine
gene activation. DMSO does not globally suppress all gene ac-
tivation; we previously reported that DMSO will actually aug-
ment IL-1 production (36).
To understand the mechanism(s) of ROI regulation of human
MCP-1 gene expression, we investigated DMSO modulation of
TNF-–induced and IL-1–induced MCP-1 secretion, mRNA
expression, and transcriptional activity. TNF- and IL-1 have
been used as classic stimuli to induce cell activation (35). Hu-
man type II alveolar epithelial cells, A549 cells, were used for
these studies. Special attention was paid to identifying specific
promoter elements responding to DMSO in MCP-1 gene ex-
pression at the transcriptional level by using the whole 5-flank-
ing region of the human MCP-1 gene.
MATERIALS AND METHODS
Reagents and materials
A549 cells were purchased from American Type Culture Col-
lection (Manassas, VA). The polyriboprobe set hCK-5, the in
vitro transcription kit, and the RPA kit were obtained from
Pharmingen (San Diego, CA). [-32P]UTP was purchased from
New England Nuclear (Cambridge, MA). The Lipofecta-
minePlus reagent transfection kit and Zero Blunt TOPO PCR
Cloning Kit were from Invitrogen (Carlsbad, CA). EDTA,
DMSO, DMTU, and TMB were obtained from Sigma (St.
Louis, MO). The human TNF-, IL-6, MCP-1, and IL-1 stan-
dards, as well as the capture and biotin-conjugated detection
antibodies for the IL-6 and MCP-1 ELISAs were purchased
from R&D (Minneapolis, MN). Horseradish peroxidase–con-
jugated streptavidin was purchased from Jackson Immuno-
Research Laboratories, Inc. (West Grove, PA). The blocking
solutions, Blotto and Casein, were obtained from Pierce (Rock-
ford, IL). Glutamine, heat-inactivated fetal bovine serum (FBS),
trypsin (0.125%), and Dulbecco’s phosphate-buffered saline
were obtained from Gibco BRL (Grand Island, NY). Dulbecco’s
modified Eagle’s medium (DMEM), penicillin, and strepto-
mycin were obtained from Bio-Whittaker (Walkersville, MD).
Erase-A-Base kit, Exonuclease III, S1 nuclease, Klenow DNA
polymerase, the pGL-3 basic vector, the pRL-TK vector, the
Dual-Luciferase Reporter Assay System, the Wizard Genomic
DNA Purification Kit, Wizard Plus SV Miniprep DNA purifi-
cation system, and restriction enzymes were from Promega
(Madison, WI). The EndoFree Plasmid Maxi Kit was from Qi-
agen (Valencia, CA). The Expand High Fidelity PCR System
was from Roche (Indianapolis, IN). The LightShift EMSA kit,
NE-PER Nuclear and Cytoplasmic Extraction Reagents and
Halt Protease Inhibitor Cocktail kit were from Pierce (Rock-
ford, IL). NF-B consensus oligonucleotides were synthesized
with a biotin label on the 5 end by Sigma Genosis (Wood-
lands, TX). The sequence is 5-AGT TGA GGG GAC TTT
CCC AGG C-3.
Cell culture
The A549 cells were grown as a monolayer in tissue-culture
flasks (Nunc, Naperville, IL) in 100% humidity and 5% CO2
at 37°C. DMEM with 10% FCS, penicillin (50 U/ml), strepto-
mycin (50 g/ml), and HEPES (25 mM) was used for culture
media. The cells were harvested with trypsin (0.125%). For each
experiment, the A549 cells were plated in 24-well culture plates
at a density of 1  105 cells/well and were grown for 36 h to
confluence in DMEM with 10% FCS. Confluent cells were
washed free of FCS with Dulbecco’s phosphate-buffered saline
and cultured in FCS-free DMEM for 48 h. On the day of use,
the A549 cell monolayer was washed with Dulbecco’s phos-
phate-buffered saline. The cells were preincubated with DMSO
immediately before TNF- or IL-1 stimulation in FCS-free
DMEM.
Enzyme-linked immunosorbent assay (ELISA)
Culture supernatants from stimulated A549 cells were re-
moved, and MCP-1 and IL-6 concentrations were measured
with ELISAs, according to our previously published methods
(3, 20). Cytokine concentrations were calculated based on stan-
dard curves.
RNA preparation
Clean instruments were used for each cell sample to elimi-
nate cross contamination. Total RNA was extracted by using
the acid guanidinium thiocyanate-phenol-chloroform extraction
procedure (7). In brief, the cells were homogenized in guani-
dinium thiocyanate followed by acid phenol/chloroform ex-
traction and precipitated with isopropanol.
Ribonuclease protection assay (RPA)
The RPA was performed by following the instructions from
Pharmingen. Riboprobe syntheses were driven by the T7 bac-
teriophage RNA polymerase with [-32P]UTP as the labeling
nucleotide. The 32P-probe (6  105 cpm/sample) was added to
tubes containing the sample RNA (4 g) dissolved in 8 l
hybridization buffer. The samples were heated to 90°C, the
temperature decreased, and RNase T1 added, followed by
treatment with proteinase K. The RNA duplexes were isolated
by extraction/precipitation as described earlier, dissolved in 
5 l gel-loading buffer, and electrophoresed in standard 5%
acrylamide/8 M urea sequencing gels. The gel was dried and
placed on XAR film (Eastman Kodak Company, Rochester,
NY) with intensifying screens and was developed at 70°C
for 4–12 h.
Construction of reporter vectors
The pGL-3 basic vector was used to construct the pGL-3 ba-
sic-human MCP-1 promoter region reporter vector (pGL-3-
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MCP-1). The sequence of the human MCP-1 gene (Y18933)
was obtained from the National Center for Biotechnology In-
formation (11). Primers used to construct the reporter vectors
are listed in Table 1. The promoter region of human MCP-1
was amplified by using the Expand High Fidelity PCR System
with chemically synthesized primers and genomic DNA as a
template. The PCR fragment was cloned into the Zero Blunt
TOPO PCR Cloning vector. The insert positive vector was di-
gested with Acc 65I and Mlu I, and then the MCP-1 promoter
fragment was subcloned into the Acc 65I (Kpn I)-Mlu I site of
the pGL-3 basic vector to generate the reporter vector.
Generation of 5 or 3 deletions of MCP-1
promoter region
To generate a series of 5 end deletions, the reporter vector
was digested with Kpn I and Bst 981 to generate 3 and 5
overhangs. The digested vector was subjected to Exonuclease
III to generate a series of 5 end deletions. Aliquots of the re-
action mixture were removed at specific time points and di-
gested with S1 nuclease, and the size of the deleted vectors
was determined by electrophoresis. After the ends were incu-
bated with Klenow DNA polymerase, the vectors were reli-
gated. These “deleted” vectors were also sequenced to verify
the 5 end of MCP-1 promoter region (shown schematically in
Results).
According to the locations of the two NF-B binding sites
(A1 and A2 sites), the GC box and TATA box reported by Ueda
et al. (31, 32), a series of 3 deletions were generated by two
PCR reactions. Fragment 72 to 8, containing the GC box
and the TATA box, which maintains the basal transcriptional
activity of the MCP-1 gene, was obtained with primer pair 34
(see Table 1 for the primers) and cloned into the NheI–Bgl II
of pGL-3 basic vector. Fragments 7537 to 6489, 7537 to
2647, 7537 to 2614, and 7537 to 2586 were ampli-
fied by PCR and cloned into the Zero Blunt TOPO PCR Cloning
vector. The cloning vectors were digested with Acc 65I (Kpn1)
and Mlu I. The target fragments were cloned into the Acc 65I
(Kpn I)-Mlu I site of the pGL-3 basic vector upstream of the
MCP-1 GC box and TATA box fragments. In this way, four
vectors were made in which fragments bp 6488 to 74, bp
2648 to 74 containing both A1 and A2 NF-B binding 
sites, 2615 to 74 containing A2 NF-B binding site, and
2587 to 74 were deleted, respectively (shown schematically
in Results).
PCR mutagenesis
Site-directed mutagenesis of both NF-B binding sites was
performed by two PCR reactions with two pairs of primers
(Table 1) and genomic DNA as the template. Two overlapping
primers, sense and antisense, were designed for the mutation
sites. The overlapping portions were the mutation sites in
which the corresponding bases were replaced to generate a
MluI restriction site at the 5 end of the primers. These two
PCR fragments were cloned into the vector. MluI and XmaI
digested the cloning vector containing the downstream frag-
ment of the MCP-1 promoter region. The target fragments were
ligated into the MluI–XmaI site of the pGL-3 basic vector. The
cloning vector, containing the upstream fragment of the MCP-
1 promoter region, was digested by KpnI  MluI. The target
fragment was ligated into the KpnI–MluI site of the pGL-3 ba-
sic vector containing the downstream fragment. All mutations
were verified by DNA sequencing (shown schematically in 
Fig. 8).
Transfection and luciferase assays
Transient co-transfection with the pGL-3 reporter vector and
the control vector pRL-TK vector into A549 cells was per-
formed by using the LipofectaminePlus method. The total
amount of DNA was 0.4 g/well. The molar ratio of the pGL-
3 reporter vector to the pRL-TK control vector was 10:1. Be-
cause of the different lengths of inserts, the difference in the
amount of DNA was supplemented with the pGL-3 basic vec-
tor. The construction and transfection of the DNA complex were
performed by following the manufacturer’s protocol. After in-
cubation of A549 cells with DNA for 6 h, DMEM with serum
was added to achieve a final serum concentration of 10%.
Meanwhile, human TNF- (2 ng/ml) or human IL-1 (1 ng/ml)
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TABLE 1. DEOXYOLIGONUCLEOTIDES USED FOR PCR AND SEQUENCING ANALYSIS
No. Sequence Site Primer Restriction site
1 5-AGCCTTGGCCACAGTGTCATCC-3 7537 to 7515 Sense
2 3-CCTTGGCTCTCCGACTCTGCGCA-5 11 to 11 Anti-sense MluI
3 5-GCTAGCCTCCGCCCTCTCTCCC-3 73 to 53 Sense NheI
4 3-CCTTGGCTCTCCGACTCTAGA-5 10 to 8 Anti-sense BglII
5 3-GTCGAAGGAAGGAGTCTGCGCA-5 6511 to 6489 Anti-sense MluI
6 3-GGTTTACGTAAGAGAAGATGCGCA-5 2671 to 2647 Anti-sense MluI
7 3-GTTTCGACGGAGGAGTGCGCA-5 2636 to 2614 Anti-sense MluI
8 3-GGTGAGTGAAGAGAGTGCGCA-5 2607 to 2586 Anti-sense MluI
9 3-GCTCTCCGACTCTGATTGGGCCC-5 7 to 16 Anti-sense XmaI
10 3-GTAAGAGAAGATGCCCTAGACTGCGCA-5 2665 to 2638 Anti-sense MluI
11 5-ACGCGTTCCAAAGCTGCCTCCTCA-3 2644 to 2619 Sense MluI
12 3-GTTTCGACGGAGGAGTCTCACTGCGCA-5 2636 to 2619 Anti-sense MluI
13 5-ACGCGTTGCACTCACTTCTCTCAC-3 2615 to 2590 Sense MluI
14 5-CTAGCAAAATAGGCTGTCCC-3 Sequencing Sense
15 5-CTTTATGTTTTTGGCGTCTTCAC-3 Sequencing Anti-sense
was added to the medium to stimulate the cells for 6 h. The
cells were washed with PBS without Ca2 and Mg2 twice,
and then 100 l 5X passive lysis buffer/well was added. The
plate was shaken for 15 min at room temperature, and then
stored at 70 °C.
After preparation of the cell extract, luciferase activities were
measured by using the Dual-Luciferase Reporter Assay System
and Packard LumiCount BL10000 (Packard Instrument Co.,
Boston, MA). The activities of the reporter vectors were re-
ported as the ratio of firefly luciferase to the Renilla control
vector. The basal activity level was subtracted. The percentage
of activity inhibition by DMSO was expressed as (stimulus -
stimulus plus DMSO)/stimulus.
The percentage suppression by DMSO was calculated for the
different reporter constructs with the equation indicated in the
figure. This was performed to demonstrate the relative reduc-
tion in reporter activity.
Electrophoretic mobility shift assay (EMSA)
A549 cells were cultured in serum-free medium for 48 h,
stimulated with TNF- (2.0 ng/ml) or IL-1 (1.0 ng/ml) for 30
min, and washed in ice-cold PBS. Nuclear extracts were pre-
pared by using the NE-PER Nuclear and Cytoplasmic Extrac-
tion Reagents by following the manufacturer’s instructions. The
protein concentration was determined with a Bradford Assay.
Binding reactions were performed by using LightShift EMSA
kit according to the manufacturer’s instructions: 20 fmol biotin
end-labeled NF-B consensus oligonucleotides and 5 g of nu-
clear extract were present in 20 l reaction volume. Reactions
were incubated for 15 min at room temperature, and DNA–pro-
tein complexes were analyzed by electrophoresis on a 6% na-
tive polyacrylamide gel in 0.5X TBE buffer at 4°C.
Statistics
Results were reported as mean  SEM. Statistical compar-
isons were performed by using a one-way ANOVA with the
Tukey comparison test and t test. All analyses were performed
by using GraphPad Prism (San Diego, CA).
RESULTS
DMSO inhibition of TNF-– or IL-1–induced
MCP-1 production
Among the proinflammatory cytokines, TNF- and IL-1
are important for the development of local inflammation and
tissue damage, and these were selected for stimulating A549
cells. We examined the concentration range of TNF- and IL-
1 capable of inducing MCP-1 by incubating cells with in-
creasing concentrations of TNF- or IL-1 for 24 h. Both TNF-
 and IL-1 significantly increased MCP-1 production by
A549 cells in a dose-dependent manner (Fig. 1A and B). The
MCP-1 levels in the culture supernatants continued to increase,
even at the highest concentrations of TNF- and IL-1. IL-1
was a more potent stimulus for MCP-1 production compared
with TNF-.
To investigate whether ROIs mediate TNF-– and IL-1–in-
duced MCP-1 synthesis by A549 cells, the cells were incubated
with DMSO (1% vol/vol) immediately before TNF- or IL-1
stimulation. As shown in Fig. 1A and B, DMSO significantly
inhibited MCP-1 production induced by all concentrations of
TNF- or IL-1.
Kinetic experiments showed that both 1,000 pg/ml TNF- and
300 pg/ml IL-1 stimulated MCP-1 production by A549 cell in
a time-dependent manner. As shown in Fig. 2A and B, both cy-
tokines markedly increased MCP-1 secretion over that sponta-
neously released from nonstimulated cells. The kinetics of TNF-
 and IL-1 induction of MCP-1 was similar, although IL-1
once again showed more potent induction. Both IL-1 and TNF-
 induced MCP-1 secretion that was detectable as early as 2 h,
and MCP-1 continued to increase up to 24 h. Pretreatment of the
cells with DMSO inhibited TNF-– or IL-1–induced MCP-1
secretion from 4 h up to 24 h after stimulation (Fig. 2A and B).
Consistent with the data from the dose–response experiment,
DMSO inhibited TNF-– and IL-1-induced MCP-1 secretion.
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FIG. 1. DMSO inhibits dose-dependent TNF- and IL-1
induced MCP-1. A549 cells were stimulated with increasing
concentrations of human TNF- (A) or IL-1 (B) (10–1,000
pg/ml) in the presence or absence of DMSO (1.0%) for 24 h.
Data shown are the means  SEM of four independent exper-
iments. #p  0.05 compared with no IL-1 or TNF-; *p 
0.05 compared with DMSO-treated cells. In some samples, the
error bar is smaller than the symbol.
Effect of DMSO on TNF-– or IL-1–stimulated
expression of MCP-1 mRNA
To determine whether DMSO inhibited the MCP-1 mRNA
level, MCP-1 mRNAs were measured with a ribonuclease pro-
tection assay (RPA). An additional advantage of the RPA is
that we may determine whether TNF- or IL-1 induces other
chemokine mRNA in the A549 cell line.
Stimulation with TNF- or IL-1 (10–1000 pg/ml) for 2 h
increased MCP-1 mRNA expression in a dose-dependent man-
ner (Fig. 3). DMSO (1%, vol/vol) decreased MCP-1 mRNA in
A549 cells at each TNF- and IL-1 dose. In parallel with the
results from the secreted protein experiments, DMSO inhib-
ited the TNF-– and IL-1–induced expression of MCP-1
mRNA.
With the poly-riboprobe set, we detected both IL-8 mRNA
and MCP-1 mRNA expression, but we did not detect mRNA
expression for other chemokines after TNF- or IL-1 stimu-
lation of A549 cells (Ltn, RANTES, IP-10, MIP-1, MIP-1,
or I-309). Consistent with a previous report (8), DMSO inhib-
ited TNF-– and IL-1–induced IL-8 mRNA expression. Cell
viability was not affected, as judged by the supernatant levels
of TNF-–stimulated IL-6 production, which were not sup-
pressed.
DMTU also inhibits MCP-1 production
As an antioxidant, DMSO inhibited TNF-– and IL-1–in-
duced MCP-1 gene expression. To provide further evidence that
other antioxidants exhibit this same capacity to decrease MCP-
1 production, DMTU was used to treat the A549 cells. As shown
in Fig. 4, DMTU inhibited TNF- (A)– and IL-1 (B)–induced
MCP-1 production by A549 cells at concentrations of 10 mM
and 20 mM without altering the cellular viability (data not
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FIG. 2. DMSO inhibits TNF- and IL-1 induction of MCP-
1 at virtually all time points. A549 cells were stimulated
with human TNF-, 1,000 pg/ml (A), or IL-1, 300 pg/ml (B),
in the presence or absence of DMSO (1.0%) for 0.5–24 h. Data
shown are means  SEM of four independent experiments.
#p  0.05 compared with no IL-1 or TNF-; *p  0.05 com-
pared with DMSO-treated cells. In some samples, the error bar
is smaller than the symbol.
FIG. 3. DMSO inhibits MCP-1 at the level of mRNA. A549
cells were stimulated with human TNF- or IL-1 in the pres-
ence or absence of 1% DMSO for 2 h. Total RNA was extracted
and measured by the ribonuclease protection assay (RPA) for
chemokine expression. The RPA demonstrates that TNF- (A)
or IL-1 induced (B) mRNA expression of MCP-1 in a dose-
dependent manner in A549 cells. DMSO suppressed the cyto-
kine-induced MCP-1 mRNA.
shown). These data indicate that the inhibitory effects of DMSO
are due to the antioxidant capacity and not to nonspecific ef-
fects.
Inhibition of NF-B by DMSO
NF-B is involved in transcriptional regulation of a wide
range of mediators, and a clear relation exists between ROIs
and the nuclear transcription factor NF-B (12, 18). We used
the EMSA to determine whether DMSO inhibited the activa-
tion of NF-B in response to TNF- or IL-1. As shown in
Fig. 5, DMSO clearly suppressed the proinflammatory cyto-
kine–induced activation of NF-B in A549 cells. The two NF-
B binding sites, A1 and A2 are located far upstream of the 5
promoter region of the MCP-1 gene (31). To confirm that
DMSO inhibited MCP-1 gene expression at the level of tran-
scription through these two NF-B binding sites, and to ascer-
tain whether other promoter elements were responsible for the
inhibition by DMSO, a series of experiments was planned to
map precisely those MCP-1 promoter elements that respond to
antioxidant regulation.
Effect of 5 deletion of MCP-1 promoter region
on reporter activity
A549 cells were transiently transfected with either the pGL-
3-MCP-1 vector or a series of pGL-3 vectors containing pro-
gressive 5-deletions of the MCP-1 promoter. The pRL-TK vec-
tor was used as control of transfection efficiency. The constructs
used are illustrated in Fig. 6A, and the results shown in Fig. 6B
and C.
After transfection, A549 cells were stimulated with 2 ng/ml
of TNF- or 1 ng/ml of IL-1 for 6 h. As shown in Fig. 6B
and C, the TNF-– and IL-1–induced activity of the full-
length pGL-3-MCP-1 reporter vector was 303  26 and 268 
33, respectively. DMSO inhibited TNF-– and IL-1–induced
activity by 56% and 44%, respectively, supporting the hypoth-
esis that DMSO suppressed TNF-– and IL-1–stimulated
MCP-1 gene expression at the transcriptional level. The per-
centage of activity inhibition by DMSO was 59% and 44% in
TNF-– and IL-1–stimulated A549 cells, respectively.
To determine whether DMSO inhibited MCP-1 gene ex-
pression through specific elements in the 5-flanking region,
A549 cells were transfected with a series of pGL-3 vectors con-
taining progressive 5-deletions of the MCP-1 promoter (de-
scribed earlier). As shown in Fig. 6B and C, the inhibition of
reporter activity by DMSO did not change significantly before
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FIG. 4. Inhibition of cytokine-induced MCP-1 secretion 
by DMTU. A549 cells were simulated with human TNF-
(1,000 pg/ml) (A) or IL-1 (300 pg/ml) (B) in the presence of
DMTU (0, 10, or 20 mM) for 24 h. Data shown are means 
SEM of four independent experiments. *p  0.05; **p  0.01
compared with no-DMTU treatment.
FIG. 5. DMSO inhibits NF-B activation in A549 cells. The
cells were incubated with 1% DMSO immediately before TNF-
 (2 ng/ml) or IL-1 (1 ng/ml) stimulation (indicated by the
top lines). After 30 min, the cells were harvested, and nuclear
extracts were prepared. The EMSA gel is representative of three
independent experiments.
the small fragment 2741 to 2616 bp was further deleted,
even though 5-deletions of the MCP-1 promoter region be-
tween bp 7537 and 6582 resulted in a 36% and 45% de-
crease of induced reporter activity by TNF- and IL-1. With
a further 5-deletion of the small fragment (-2741 to 2616
bp), where the A1 NF-B binding site is located, TNF- and
IL-1 could no longer induce MCP-1 reporter activity. Further
deletions over 2616 toward downstream did not further alter
the induction of TNF- or IL-1 and the inhibition of DMSO
on the activity of the MCP-1 reporter, as anticipated. To dem-
onstrate that the induction of promoter activity up to site 2741
could always be suppressed by DMSO, the percentage reduc-
tion in activity is also displayed in the lower part of Fig. 6B
and C. The data suggest that the elements located upstream of
the A1 B site are not involved in the inhibition of DMSO, al-
though they participate in sustaining the maximal expression of
the MCP-1 gene in response to proinflammatory cytokines.
Effect of 3 deletions of MCP-1 promoter region
on reporter activity
Figure 6 evaluated the effect of 5 deletions on antioxidant
regulation of MCP-1. To clarify the relation between the NF-
B binding sites and other potential transcription factor binding
sites, and whether DMSO modulates transcription factor bind-
ing at these sites, a series of pGL-3 vectors containing 3 dele-
tions of the promoter region of MCP-1 gene were constructed.
As shown in Fig. 6B and C, the deletion of 70 to 1 resulted
in the complete loss of even the basal transcriptional activity of
the reporter gene. This is consistent with the report of Ueda et
al. (32) that the GC box controlling the basal transcriptional ac-
tivity of MCP-1 gene was located between 64 bp and 59 bp.
Fragment 73 to 8, which contains the GC box and TATA
box of the MCP-1 gene, was obtained with the primer pair 34
(Table 1) and was cloned into the NheI–BglII restriction site of
the pGL-3 basic vector. Cloning of fragments 7537 to 2586,
7537 to 2614, 7537 to 2647, and 7537 to 6489 into
the Acc 65I (KpnI)-MluI site of the pGL-3 basic vector upstream
of the MCP-1 GC box fragment resulted in deletions of frag-
ments 2587 to 74 (D-N-1), 2615 to 74 (D-N-2), 2648
to 74 (D-N-3), and 6488 to 74 (D-N-4) (Fig. 7).
The deletion of 2587 to 74 base pairs (reporter D-N-1;
Fig. 7) resulted in a 50% and 55% decrease of the TNF-– and
IL-1–induced reporter activities. Although the cytokine-in-
duced MCP-1 expression was reduced, DMSO was still able to
exhibit significant suppression of the induced reporter activity.
Removal of 29 additional nucleotides from 2615 to 2586,
which includes the A2 NF-B binding site (GGGAATTTCC),
resulted in essentially complete loss of stimulus-induced re-
porter activity. Further deletion of the A1 NF-B binding site
(GGGAACTTCC) had no additional suppressive effect on the
reporter activities, although it must be acknowledged that the
levels were already lowered so dramatically that it would be
nearly impossible to observe any further reduction. These data
suggest strongly that transcription-factor binding sites in this
downstream fragment participated in the maximal expression
of the MCP-1 gene.
As shown in Fig. 6, the deletion of 7537 to 6852 resulted
in a dramatic decrease of cytokine-induced reporter activities,
implying that this fragment plays a role in regulating MCP-1
gene expression. Vector D-N-4 was constructed with deletion
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FIG. 6. Analysis of the human MCP-1 5 flanking re-
gion. (A) The size of the 5 promoter region of the MCP-1
linked to the luciferase gene fragment is indicated by the open
box preceding the luciferase gene (LUC). The activity of each
reporter vector is expressed as the ratio of firefly luciferase ac-
tivity to Renilla luciferase activity in each cell extract after sub-
traction of the basal activity (B, C). The lower portion of each
graph displays the percentage inhibition exerted by DMSO. The
cells were stimulated with TNF- (2 ng/ml; B) or IL-1 (1
ng/ml; C) in the presence or absence of DMSO. A dramatic
loss of stimulated reporter activity occurs when the fragment
length is decreased from 2741 to 2616. Each of the trun-
cated reporters has nearly equivalent inhibition of activity by
DMSO up to the point at which activity is no longer induced.
The experiments were repeated four to 17 times, and the results
are expressed as the mean  SEM.
of fragment 6488 to 74. D-N-4 induced a minimal amount
of reporter activity compared with the other constructs (data not
shown) and did not respond to the stimulation with TNF- or
IL-1. DMSO was without effect because the induced levels
were so low. These data indicate that additional elements par-
ticipated in the maximal expression of the MCP-1 gene, which
were dependent on the other elements, especially NF-B bind-
ing sites, but these additional elements were not responsive to
TNF- or IL-1 stimulation.
Effects of mutation or deletion of NF-B binding
sites on reporter activity
The data show that the 5 or 3 deletions of the MCP-1 pro-
moter region without altering either the A1 or A2 NF-B bind-
ing sites decreased the magnitude of MCP-1 gene expression,
but did not result in complete loss of stimulus-induced tran-
scriptional activity and the inhibition of DMSO. Additional re-
moval of one NF-B binding site, either in 5 or 3 deletion,
completely abolished the response to TNF- and IL-1. These
data strongly imply that the function of the regulatory elements
located in either the up- or the downstream position depends
on both NF-B binding sites. To determine the relation between
the two NF-B binding sites, and the dependence of other ele-
ments on NF-B binding sites, mutations at either NF-B bind-
ing sites or deletion of both sites were induced separately on
the background of the whole 5-flanking promoter region of the
MCP-1 gene.
As shown in Fig. 8, mutation of the A1 NF-B binding site
(vector N-M-1) resulted in a 76% and 79% decrease of the re-
porter activity in response to TNF- and IL-1, respectively.
The mutation at the A2 NF-B binding site (vector N-M-2) re-
sulted in an 88% and 94% decrease of promoter activity, re-
spectively. These data indicate that the downstream NF-B
binding site was slightly more powerful than the upstream one
in controlling TNF-– and IL-1–induced MCP-1 gene ex-
pression. Although mutation of a single NF-B binding site de-
creased MCP-1 gene expression, DMSO was still capable of
inhibiting the cytokine induced reporter activity. Deletion of
both NF-B binding sites completely eliminated the reporter
response to either TNF- or IL-1. Analysis of the mutation
and deletion data demonstrated that the regulatory effects of the
other elements is dependant on the activity of NF-B binding
sites, including the cooperation between both NF-B binding
sites. Additionally, DMSO inhibited TNF-– and IL-1–in-
duced MCP-1 gene expression through affecting the activity of
both NF-B binding sites.
Exogenous ROIs induce MCP-1 gene expression
through NF-B binding sites
As shown earlier, the inhibition of DMSO on TNF-– and
IL-1–induced MCP-1 gene expression depended on NF-B
binding sites. To identify directly whether ROIs play roles in
MCP-1 gene expression through NF-B binding sites, O2 pro-
duced by the xanthine-xanthine oxidase (X-XO) system was
used to stimulate A549 cells. O2 generated by X-XO (1.6 mM
to 3 mU/ml) for 6 h significantly stimulated A549 cells to pro-
duce MCP-1 (259.7  50.1 vs. 622.7  105.3 pg/ml, n  4,
p  0.05). As shown in Fig. 9, X-XO induced MCP-1 reporter
activity in pGL-3-MCP-1, N-M-1, and N-M-2 transfected A549
cells. For each of these reporters, the oxidant-induced activity
was nearly completely abolished by DMSO. Mutation of the
A1 NF-B binding site (vector N-M-1) resulted in a 22.4% de-
crease of the reporter activity in response to X-XO (1.6 mM to
3 mU/ml). The mutation at the A2 NF-B binding site (vector
N-M-2) resulted in a 38.3% decrease of promoter activity.
These data indicated that the downstream A2 NF-B binding
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FIG. 7. Analysis of downstream deletions in the promoter region of MCP-1 gene. The reporter vectors containing down-
stream deletions were cotransfected, as in Fig. 6. (A) The 3 deletions in the human MCP-1 promoter region linked to the lucif-
erase gene are indicated. The NF-B binding sites are indicated by black boxes. LUC indicates the luciferase gene. Open boxes,
The deleted fragments. (B) The activity of reporter vectors shown from (A) is expressed as the ratio of firefly luciferase activ-
ity to Renilla activity after subtraction of the basal activity. Values are expressed as mean  SEM, n  4.
site was slightly more powerful than the upstream one in reg-
ulating ROI-induced MCP-1 gene expression, consistent with
the data in Fig. 8. Deletion of both NF-B binding sites (B-N-
D) completely eliminated the reporter response to X-XO.
DISCUSSION
In this study, we showed that both TNF- and IL-1 stimu-
lated MCP-1 mRNA expression and protein production in a
similar dose-dependent and kinetic pattern in A549 cells, a hu-
man type II alveolar epithelial cell line. We demonstrated that
the antioxidant DMSO decreased MCP-1 mRNA expression
and protein production in TNF-– and IL-1–stimulated A549
cells in dose-dependent manner. DMTU, another antioxidant,
also inhibited cytokine-induced MCP-1 protein secretion. By
using a reporter vector containing the whole known 5-flank-
ing region of human MCP-1 and EMSA, we verified that
DMSO inhibits cytokine-stimulated MCP-1 production at the
transcriptional level through suppressing NF-B. Moreover, the
two proximal NF-B binding sites(15, 31) are critical for
stimulus-induced enhancer activities. Mutation of either of the
NF-B binding sites decreased enhancer activity by TNF- and
IL-1. Deletion of both sites completely abolished TNF-– and
IL-1–induced transcriptional activity. To further confirm the
importance of these sites, direct stimulation with ROI induced
reporter activity, which was significantly reduced by DMSO.
Several recent studies have shown that ROI may act as in-
tracellular second messengers to mediate production of certain
chemokines, which are potent chemoattractants for inflamma-
tory cells. In this setting, amplification of tissue damage may
also occur through infiltration of inflammatory cells, either
acutely or chronically (13). The MCP-1 gene can be induced
by numerous stimuli, including cytokines whose functions are
partially mediated by ROIs (28). Among the cytokines secreted
by infiltrating macrophages, TNF- and IL-1 are important
for the development and regulation of local inflammation and
tissue damage (29). DeForge et al. (9) and Barrett et al. (2) re-
ported that ROIs serve as second messengers to induce IL-8
gene expression in different cells, including human type II alve-
olar epithelial cells. Fat-storing cells produce MCP-1 in re-
sponse to oxygen free radical stimulation (37).
Several functional binding sites for transcription factors are
present in the 5-flanking region of the human MCP-1 gene, in-
cluding NF-B , Sp 1, AP-1, TRE, and NF-IL-6(11, 21–24, 32).
Two closely located NF-B binding sites, A1 and A2 (31), were
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FIG. 8. Analysis of mutations and deletions of NF-B binding sites in the MCP-1 promoter. (A) Vector constructs. 
NF-B binding sites are indicated by black (not mutated) or shaded (mutated) boxes. The lower-case letters indicate the mutated
base pairs. N-M-1 and N-M-2 have the NF-B binding sites mutated, whereas B-N-D has both bindings sites deleted. The MluI
restriction site is indicated. (B) The activity of reporter vectors shown in (A) is expressed as the ratio of firefly luciferase activ-
ity to Renilla luciferase activity after subtraction of the basal activity. Values are expressed as mean  SEM, n  4.
FIG. 9. ROI induction of MCP-1 reporter activity through
NF-B binding sites. After transfection with pGL-3-MCP-1,
N-M-1, N-M-2, and B-N-D, as indicated in Fig. 8A, A549 cells
were stimulated with X-XO (1.6 mM to 3 mU/ml) for 6 h. The
induced activity of reporter vectors is expressed as the ratio of
firefly luciferase activity to Renilla luciferase activity after sub-
traction of the basal activity. Both NF-B sites modulate re-
porter activity. Deletion of both sites completely eliminates the
ability of ROIs to induce MCP-1 reporter activity. Values are
expressed as mean  SEM; n  3. **p  0.01 compared with
pGL-3-MCP-1. #p  0.05 compared with N-M-1.
identified in the 5-flanking region of the human MCP-1 gene
(32). Our data showed that the existence of both NF-B bind-
ing sites was important for transcription of the human MCP-1
gene and tightly related to the inhibiting effect of DMSO on
MCP-1 gene expression. Other investigators also demonstrated
that multiple sites regulate chemokine induction, such as IL-8
(25). The deletion of these two NF-B binding sites resulted in
the complete abolishment of TNF-– and IL-1–induced hu-
man MCP-1 gene expression, indicating that the regulatory
function of other transcription factors for MCP-1 gene expres-
sion depends on the activation of these two B sites. Further-
more, our study supplies information about the relation between
the NF-B binding sites and the other transcription factors. Up-
stream and downstream deletions of the 5 flanking region of
the MCP-1 gene resulted in a decrease in reporter activity. If
only one NF-B binding site was included in the 5 or 3 dele-
tion, the cytokine-induced responses were essentially abolished.
This suggests that any other transcription factor binding sites
that participate in the stimulus-induced expression of the MCP-
1 gene depend on the activation and coexistence of the NF-B
binding sites. The typical example is the deletion of an 1-kb
fragment in the far upstream position of the 5-flanking region.
This deletion resulted in a dramatic decrease of cytokine-in-
duced reporter gene activity through unknown elements located
in this fragment, which requires more work to identify. Inter-
estingly, mutation of these sites did not reduce the ability of
ROIs to induce promoter activity.
The deletion of 5 fragments, not including the A1 NF-B
binding site, and 3 fragments, not including A2 NF-B bind-
ing site, resulted in a partial decrease of cytokine-induced MCP-
1 promoter activities, but the inhibiting potential of DMSO 
was not altered. The 5 or 3 deletion that included only one
NF-B binding site resulted in near-complete abolishment of
cytokine-induced MCP-1 promoter activity, indicating that the
inhibition of DMSO directly related to the two B sites and that
the elements located in the upstream or downstream fragment
of both B sites are not involved in the inhibition of DMSO.
The electromobility shift assay data confirmed that DMSO in-
hibited proinflammatory cytokine-induced NF-B activation.
More-direct evidence showed that exogenous ROIs induce
MCP-1 gene expression in A549 cells through the two NF-B
binding sites, which was inhibited by DMSO. As a free radical
scavenger and antioxidant, DMSO has been found to inhibit the
activation of the NF-àB in a number of cell lines. Kelly et al.
(14) reported that DMSO decreased the level of LPS-induced
NF-B activation in the J774 macrophage-like cell line. DMSO
also inhibited X/XO induced increases in NF-B and MCP-1
production from U937 cells (17). These observations were ex-
tended to the in vivo setting, where therapeutic treatment with
DMSO inhibited sepsis-induced activation of NF-B and 
AP-1, resulting in the suppression of ICAM-1 gene expression
in the livers of septic rats (4, 5). In galactosamine-sensitized
C3Heb/FeJ mice, DMSO effectively inhibited endotoxin- and
TNF-–induced hepatic NF-àB activation (10). These previous
reports and our present data demonstrate the importance of
ROIs in the regulation of MCP-1 production, and by extension,
regulation of inflammation.
Besides inhibiting the direct damage of ROI produced by in-
filtrating leukocytes, antioxidants could also inhibit ROI-medi-
ated chemokine production from inflammatory cells. Decreased
chemokine production should result in decreased inflammatory
cell recruitment. We demonstrated here that the human alveo-
lar type II cell line, A549, was able to produce the CC chemo-
kine MCP-1 in response to proinflammatory cytokines. DMSO
significantly inhibited this chemokine synthesis. The data im-
ply that one more mechanism supports antioxidant treatment in
lung injury. Antioxidants inhibited the ROI-mediated chemo-
kine production from the nonimmune cells, the resident cells,
at the local inflammatory site. This will consequently result in
decreased leukocyte infiltration and ROI production.
With the poly-riboprobe set, we did not detect mRNA ex-
pression for chemokines other than MCP-1 and IL-8. These
agree with those of Lakshminarayanan et al. (16), who also did
not detect mRNA expression of Ltn, IP-10, MIP-1, MIP-1,
and I-309 in TNF-–treated A549 cells by using the same poly-
riboprobe set.
Our study suggests that decreasing intracellular ROIs induced
by proinflammatory cytokine stimulation has the potential to
decrease inflammatory cell infiltration by lowering the produc-
tion of chemokines. The mechanism of this attenuated chemo-
kine production occurs via inhibition of the transcriptional
regulatory factor NF-B, which binds to specific promoter
elements in the MCP-1 gene. These data imply that a portion
of the beneficial effects of antioxidants may be through selec-
tive reduction of the synthesis of chemokines.
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